 |
|
|
| |
|
Scientific Advisors
|
Eric Gordon, Ph.D.
Palantir Consulting
Dr. Gordon is a partner at Skyline Ventures and has been a distinguished medicinal chemist, company founder and senior executive since the early 1970s. He was head of medicinal chemistry at Squibb and Bristol Myers Squibb in Princeton, where he worked for 18 years. In 1992, he was Vice President of Research and Director of Chemistry at Affymax in Palo Alto, and in 1996, he became scientific co-founder, President and Chief Scientific Officer of Versicor (later Vicuron Pharmaceuticals, which was acquired by Pfizer in 2005). He is an accepted authority on combinatorial chemistry, medicinal chemistry, and creating drugs through enzyme inhibition.
He received his Ph.D. and M.S. in medicinal chemistry from the University of Wisconsin in Madison and conducted post-doctoral work at Yale University.
|
 |
|
|
|
Andrew G. Myers, Ph.D.
Professor of Chemistry and Chemical Biology, Harvard University
Dr. Myers is currently a Professor of Chemistry and Chemical Biology at Harvard University. He began his academic career as an Assistant Professor of Chemistry at the California Institute of Technology (1986-1991) where he was later Associate Professor (1991-1994) and Professor (1994-1998).
Dr. Myers received the Eli Lilly Grantee Award and the NSF Presidential Young Investigator Award in 1989; a David and Lucile Packard Fellowship and an Alfred P. Sloan Research Fellowship, the ICI Excellence in Chemistry Award, the Camille and Henry Dreyfus Teacher-Scholar Award in 1990; the American Cyanamid Young Faculty Award in Organic Chemistry in 1991; Pfizer Research Awards in Synthetic Organic Chemistry (1992-1995); the Arthur C. Cope Scholar Award in 1993; the Thieme-IUPAC Award in Synthetic Organic Chemistry in 1998; the ACS Award for Creative Work in Synthetic Organic Chemistry; and the Novartis Chemistry Lectureship Award in 2002.
|
|
|
|
|
Paul J. Reider, Ph.D.
Pharmaceutical Specialist, Department of Chemistry, Princeton University
Dr. Reider joined the faculty of Princeton University in 2008 where his research is focused on new drugs for Malaria, TB and other neglected diseases. During his 28 years in the pharmaceutical industry he has directly contributed to the discovery, identification, development or registration of 14 approved drugs. After post-doctoral research as an NIH National Research Service Awardee at Colorado State University, Dr. Reider joined Merck where he was later Vice President of Process Chemistry. Additionally, Dr. Reider served as the Worldwide Head of Chemistry Research & Discovery at Amgen (2002-2007).
Dr. Reider received his A.B. (Psychology) at New York University's Washington Square College and his Ph.D. (Organic Chemistry) at the University of Vermont. Paul is an inventor on many patents, an author of more than 170 scientific papers, and the winner of numerous awards. He has served on the visiting committees for Harvard University, California Institute of Technology, and the University of California, Santa Barbara, and on the Editorial Advisory Boards of the Journal of the American Chemical Society, the Journal of Organic Chemistry, and Organic Letters. He is also a Senior Editor of Current Opinion in Drug Discovery & Development, and Science of Synthesis. |
|
|
|
|
Joseph S. Solomkin, M.D.
Professor emeritus, Department of Surgery,
University of Cincinnati College of Medicine
Dr. Solomkin is currently Professor emeritus in the Department of Surgery at the University of Cincinnati College of Medicine. After completing his undergraduate degree at Harvard University, Dr. Solomkin pursued his medical education at the Albert Einstein College of Medicine in New York. Following his internship at that facility, Dr. Solomkin served as a captain in the U.S. Army Medical Corps with service in Vietnam and Thailand. Dr. Solomkin then received his surgical training at the University of Minnesota Hospitals, and there did a fellowship in surgical infections with Dr. Richard Simmons. Dr. Solomkin then joined the Department of Surgery at the University of Cincinnati College of Medicine. His clinical practice has ranged from burn care to trauma to general surgery and surgical critical care. Dr. Solomkin has been involved as the principal investigator of several Phase 2 and 3 trials of antibiotics in surgical infections, particularly regarding intra-abdominal, soft tissue, and fungal infections, and ventilator-associated pneumonia in trauma patients. |
|
|
|
|
Joaquim Trias, Ph.D.
President, JPTS Consulting
Dr. Trias has spent over 25 years in anti-infectives and drug discovery, in both academia and industry. His research interests have focused on mechanism of action of new drugs and mechanism of resistance to antibiotics. Dr. Trias obtained his Ph.D. at the University of Barcelona and completed his post-doctoral training at the University of California at Berkeley. He has held different academic positions, he was previously a Research Fellow at the School of Medicine Pitié–Salpêtrière of the University of Paris VI, and later on was also appointed Professor of Microbiology at the Faculty of Pharmacy of the University of Barcelona. In 1990 he joined Microcide Pharmaceuticals at inception until its successful IPO, where he initiated various discovery programs in infectious diseases. He left Microcide to join Versicor (later named Vicuron) where he was Vice President of Drug Discovery Research at Vicuron and directed the internal discovery projects‚ from concept to clinical candidate and participated in the clinical development programs. Vicuron completed a successful IPO and was subsequently acquired by Pfizer. He is was co-founder of Peninsula (acquired by Jonhson and Johnson), Anthera, and Tetraphase. He currently serves as a consultant and advisor (through JTPS Consulting) where he advises Venture Capital firms and Pharmaceutical Companies. |
|
|
|
Clinical Advisory Board
|
Helen W. Boucher, M.D.
New England Medical Center, Tufts University
Helen Boucher is Assistant Professor of Medicine, Program Director of the Infectious Diseases Fellowship, and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts University New England Medical Center in Boston, Massachusetts. Dr. Boucher received her medical degree from the University of Texas Medical School at Houston. She completed her internship, residency and chief residency in Internal Medicine at the New England Deaconess Hospital and her clinical and research fellowships in infectious diseases at the Beth Israel Deaconess Medical Center. Dr. Boucher is board certified in internal medicine and infectious diseases.
Dr. Boucher’s clinical interests include infections in immunocompromised patients with an emphasis on transplant-related bacterial and fungal infections and human immunodeficiency virus as well as Staphylococcus aureus infections. Her research interests focus on S. aureus and the development of new anti-infective agents. She is the author or coauthor of numerous abstracts, chapters and peer-reviewed articles, which have been published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and Drugs.
Dr. Boucher is a member of several professional organizations, among them the Infectious Diseases Society of America, the American Society for Microbiology, and the American Medical Association. In 1998, the Massachusetts Infectious Diseases Society awarded Dr. Boucher the Edward H. Kass Award for Clinical Excellence. In May 2006, she was elected to the Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) and in October 2007, she was elected to the Research Committee of the IDSA.
|
|
|
|
|
Thomas M. File Jr., M.D., M.Sc.
Summa Health System and Northeastern Ohio Universities College of Medicine
Thomas M. File Jr. is Chief of the Infectious Disease Service and Director of HIV Research at Summa Health System in Akron. Ohio, and Professor of Internal Medicine, Master Teacher, and Head of the Infectious Disease Section at the Northeastern Ohio Universities College of Medicine in Rootstown, Ohio. After graduating from medical school at the University of Michigan, Ann Arbor in 1972, Dr. File received his Master of Science in medical microbiology from Ohio State University in Columbus in 1977, where he also completed his fellowship in infectious diseases. Dr. File is a Master of the American College of Physicians, a Fellow and member of the Board of Directors of the Infectious Diseases Society of America (IDSA) and a Fellow of the American College of Chest Physicians. He is Vice President of the Board of Directors of the National Foundation for Infectious Diseases and is a member of many other professional societies, including the American Society for Microbiology, the American Thoracic Society (ATS), and the American Society of Hospital Epidemiologists. He is the past Chairperson of the Standards and Practice Guidelines Committee and past president of the IDSA and member of the IDSA guidelines panels for Community-acquired pneumonia, Hospital-associated pneumonia, Influenza, and Sinusitis. He is a member of the Pneumonia Technical Expert Panel for Inpatient Measures for CMS.
Dr. File’s primary interests include community-acquired respiratory tract infections, bacterial resistance in respiratory infections, infections in patients with diabetes, soft tissue infections, and evaluation of new antimicrobial agents. A frequent lecturer both nationally and internationally, Dr. File has published more than 200 articles, abstracts, and textbook chapters, focusing on the diagnosis, etiology, and treatment of infectious diseases, especially on respiratory tract infections. He co-authored File TM Jr. and Stevens DL Contemporary Diagnosis and Management of Skin and Soft Tissue Infections, 2nd Ed (2007, published by Handbooks in Health Care Co.) and co-edited Tan JS, File TM Jr., Salata RA, Tan MJ (eds.) Expert Guide to Infectious Diseases, 2nd edition(2008, published by ACP Press, Phil.). In addition, he is Editor-in-Chief of Infectious Diseases in Clinical Practice.
|
|
|
|
|
David Livermore, Ph.D.
UK Government Health Protection Agency's Antibiotic Resistance Monitoring and Reference Laboratory (ARMRL)
David Livermore is the Director of the United Kingdom’s Government Health Protection Agency's Antibiotic Resistance Monitoring and Reference Laboratory (ARMRL), where he has responsibility for investigating bacteria with unusual resistance phenotypes and assessing their mechanisms and public health importance. Dr. Livermore serves or has served on various editorial boards and scientific committees, including the UK Government’s Specialist Advisory Committee on Antibiotic Resistance from 2001-2007.
He received his B.Sc. at Heriot-Watt University in Edinburgh in 1978 and his Ph.D. from the University of London in 1983. He worked at the London Hospital Medical College from 1980 until 1997, then moving to the Central Public Health Laboratory (CPHL), which became part of the Health Protection Agency in 2003. He has published more than 300 papers on antibiotics and resistance in peer-reviewed journals.
|
|
|
|
|
Robert C. Moellering, Jr., M.D.
Harvard Medical School
Dr. Moellering is the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School. He served as Physician-in-Chief at the New England Deaconess Hospital from 1981 until 1996. He subsequently served as the Herrman L. Blumgart Professor of Medicine at Harvard Medical School, and Physician-in-Chief and Chairman of the Department of Medicine at the Beth Israel Deaconess Medical Center (BIDMC) in Boston through 2005. During that period he was also President and CEO of Harvard Medical Faculty Physicians at BIDMC.
Trained as an infectious diseases specialist, Dr. Moellering has been actively involved in laboratory research for the past 35 years carrying out numerous studies of the mechanism of action and mechanisms of resistance to antimicrobial agents and his work is reported in over 400 publications in scientific journals. He is a Fellow of the Infectious Diseases Society of America, Master of the American College of Physicians, and an Honorary Fellow of the Royal College of Physicians.
|
|
|
|
|
David P. Nicolau, Pharm.D., FCCP, FIDSA
Hartford Hospital
David Nicolau is Director for the Center for Anti-Infective Research and Development and Coordinator for Research in the Department of Medicine, Division of Infectious Diseases and Pharmacy, at Hartford Hospital in Hartford, Connecticut. After graduating from Northeastern University, he completed a residency in hospital pharmacy at Boston University Medical Center. After receiving his Pharm.D. from the Medical University of South Carolina, Dr. Nicolau completed a residency in adult internal medicine at the University’s affiliated hospital and a fellowship in Infectious Diseases at Hartford Hospital.
Dr. Nicolau’s research activities involve a wide range of preclinical drug development studies to assess the in vitro potency, in vivo efficacy and toxicity profiles of novel compounds. He has been a principal investigator for Phase 1-4 studies, as well as Investigational New Drug applications. Dr. Nicolau is also widely recognized for his efforts focusing on the development of antimicrobial utilization strategies to improve outcomes and reduce the cost of care in the infected patient. His investigations are reported in more than 400 publications, 250 abstracts and 500 local, national or international presentations.
|
|
|
|
|
Louis B. Rice, M.D.
The Warren Alpert Medical School, Brown University
Dr. Rice serves as chair of the department of medicine at The Warren Alpert Medical School, Brown University, and as chief of medicine at Rhode Island and The Miriam hospitals. Previously, Dr. Rice served as professor of medicine at Case Western Reserve University, Cleveland, Ohio. Dr. Rice is board certified in infectious diseases and serves as Chief of the Medical Service at the Cleveland VAMC. His research interests focus on the mechanisms of antimicrobial resistance, the transfer of resistance to antimicrobial agents, and the influence of antibiotic administration on the emergence of resistance in the clinical setting. Among his many committee appointments Dr. Rice serves as a Member of the Program Committee of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Dr. Rice holds an A.B. from Harvard University and earned his M.D. at Columbia University.
|
|
|
|
|
David Shlaes, M.D., Ph.D.
Anti-Infectives Consulting, LLC
Dr. Shlaes has had a 30-year career in anti-infectives spanning academia and industry with a long-standing scientific interest in antimicrobial resistance. In 1991 he was appointed Professor of Medicine at Case Western Reserve University. In 1996, Dr. Shlaes became Vice President for Infectious Diseases at Wyeth Research for six years, assuming responsibility for the strategic direction for infectious diseases within Wyeth. In 1998 Dr. Shlaes was the cover feature in the April issue of Business Week dedicated to antibiotics research. In 2002, Dr. Shlaes became Executive Vice President, Research and Development for Idenix Pharmaceuticals, a company located in Cambridge, MA focused on the discovery and development of antivirals. In 2005, he left Idenix to form a consulting company for the pharmaceutical industry (Anti-Infectives Consulting, LLC). He was recently an Independent Director for Novexel, S.A, an anti-infectives biotech in Paris that was just sold to Astra-Zeneca. He consults for a number of other biotechnology companies focused on anti-infectives and frequently works with venture capital firms in the evaluation of anti-infective companies.
|
|
|
|
|
|
|
|
|
